Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)Defense World · Oct 17, 2026
DBV Technologies (NASDAQ:DBVT) Reaches New 1-Year Low – What’s Next?Defense World · Oct 16, 2026
DBV Technologies (NASDAQ:DBVT) Sets New 1-Year Low – Time to Sell?Defense World · Oct 8, 2026
DBV Technologies (NASDAQ:DBVT) Shares Gap Down – What’s Next?Defense World · Oct 3, 2026
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 YearsGlobeNewsWire · Sep 29, 2026
DBV Technologies (NASDAQ:DBVT) versus XTL Biopharmaceuticals (NASDAQ:XTLB) Financial AnalysisDefense World · Sep 25, 2026DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 16, 2026 | -$0.12 | -$0.14 | Miss |
| Apr 30, 2026 | -$0.14 | -$0.56 | Miss |
| Mar 27, 2026 | -$1.30 | -$1.15 | Beat |
| Oct 28, 2025 | -$1.45 | -$0.34 | Beat |
| Jul 30, 2025 | -$0.21 | -$1.55 | Miss |
| Apr 30, 2025 | -$0.24 | -$0.26 | Miss |